Great Novel Therapeutics Biotech & Medicals (ROCO:7427) EBIT : NT$-104.80 Mil (TTM As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Great Novel Therapeutics Biotech & Medicals EBIT?

Great Novel Therapeutics Biotech & Medicals's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2024 was NT$-42.91 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2024 was NT$-104.80 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Great Novel Therapeutics Biotech & Medicals's annualized ROC % for the quarter that ended in Dec. 2024 was -129.32%. Great Novel Therapeutics Biotech & Medicals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -584.56%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Great Novel Therapeutics Biotech & Medicals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -8.77%.

Great Novel Therapeutics Biotech & Medicals EBIT Historical Data

The historical data trend for Great Novel Therapeutics Biotech & Medicals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Great Novel Therapeutics Biotech & Medicals EBIT Chart

Great Novel Therapeutics Biotech & Medicals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBIT

Get a 7-Day Free Trial

-31.24

-36.52

-55.78

-60.91

-104.80

Great Novel Therapeutics Biotech & Medicals Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
EBIT	Get a 7-Day Free Trial							-27.15	-35.51	-25.39	-61.89	-42.91

Competitive Comparison of Great Novel Therapeutics Biotech & Medicals's EBIT

For the Biotechnology subindustry, Great Novel Therapeutics Biotech & Medicals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Great Novel Therapeutics Biotech & Medicals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Great Novel Therapeutics Biotech & Medicals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Great Novel Therapeutics Biotech & Medicals's EV-to-EBIT falls into.

Save Embed

;

Save Embed

;

Great Novel Therapeutics Biotech & Medicals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-104.80 Mil.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Great Novel Therapeutics Biotech & Medicals's annualized ROC % for the quarter that ended in Dec. 2024 is calculated as:

	ROC % (Q: Dec. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2024 )	+	Invested Capital (Q: Dec. 2024 ))	/ count )
=	-95.168 * ( 1 - 0% )	/	( (80.165	+	67.015)	/ 2 )
=	-95.168	/	73.59
=	-129.32 %

where

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	700.763	-	14.167	-	( 612.18	-	max(0, 20.971	-	627.402	+	612.18	))
=	80.165

	Invested Capital		(Q: Dec. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	662.6	-	18.711	-	( 582.758	-	max(0, 21.823	-	598.697	+	582.758	))
=	67.015

Note: The Operating Income data used here is two times the semi-annual (Dec. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Great Novel Therapeutics Biotech & Medicals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2024		Q: Dec. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-85.81	/	( ( (15.539 + max(0.18600000000008, 0))	+	(13.634 + max(-3.547, 0)) )	/	2 )
=	-85.81	/	( ( 15.725	+	13.634 )	/	2 )
=	-85.81	/	14.6795
=	-584.56 %

where Working Capital is:

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.361	+	3.142	+	11.261)	-	(14.167	+	0	+	0.411)
=	0.18600000000008

	Working Capital		(Q: Dec. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.716	+	3.013	+	11.538)	-	(18.711	+	0	+	0.103)
=	-3.547

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Great Novel Therapeutics Biotech & Medicals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2024 )
	=	-104.799	/	1195.456
	=	-8.77 %

Great Novel Therapeutics Biotech & Medicals EBIT Related Terms

Thank you for viewing the detailed overview of Great Novel Therapeutics Biotech & Medicals's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Great Novel Therapeutics Biotech & Medicals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Great Novel Therapeutics Biotech & Medicals (ROCO:7427) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.3, Park Street, Room WR-06, 17th Floor, Nangang District, Taipei, TWN, 11503

Website

http://www.gntbm.com.tw

Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.

Great Novel Therapeutics Biotech & Medicals Headlines

No Headlines